StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research note released on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Down 2.3 %
LPCN stock opened at $4.62 on Friday. Lipocine has a twelve month low of $2.31 and a twelve month high of $7.15. The stock has a market capitalization of $24.72 million, a price-to-earnings ratio of -1.51 and a beta of 1.05. The firm’s fifty day simple moving average is $4.60 and its two-hundred day simple moving average is $3.59.
Lipocine (NASDAQ:LPCN – Get Free Report) last issued its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.11. The firm had revenue of $0.22 million for the quarter. As a group, equities research analysts expect that Lipocine will post -1.49 EPS for the current year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Read More
- Five stocks we like better than Lipocine
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- There Are Different Types of Stock To Invest In
- Hilton Demonstrates Asset Light is Right for Investors
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
